Department of Gastrointestinal Surgery, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima Bunkyo-Ku, Tokyo, 113-8510, Japan.
Department of Surgery, Kojinkai Daiichi Hospital, Tokyo, Japan.
Int J Colorectal Dis. 2021 Jun;36(6):1243-1250. doi: 10.1007/s00384-021-03856-3. Epub 2021 Jan 30.
Locally recurrent rectal cancer (LRRC) has a tremendous impact on prognosis as well as the quality of life. Because of the low incidence and various recurrence patterns, the treatment outcome of LRRC is not fully elucidated. The current study aimed to evaluate the prognosis and identify the prognosticators in patients with LRRC.
We conducted a multicenter study at 24 hospitals in Japan. Patients with primary rectal cancer who underwent curative resection between 1997 and 2012 and developed local recurrence only as a first recurrent event were recruited. The primary outcome of our study was overall survival (OS) after a diagnosis of LRRC.
Four hundred and ninety-eight patients were included in the study. Of these, 213 (42.8%) underwent surgical resection; this was associated with the best 5-year OS rate of 52%, followed by carbon ion/proton therapy (44%). Among LRRC patients, undifferentiated type, T4, high CEA level, and high CA19-9 level were independent prognosticators of OS (hazard ratio (HR) = 1.83, P = 0.008, HR = 1.54, P = 0.004, HR = 1.35, P = 0.03, and HR = 1.58, P = 0.003, respectively).
This large-scale cohort study showed that surgical resection led to a favorable prognosis compared to other treatments for LRRC. Therefore, surgical resection should be considered whenever feasible for LRRC patients. In addition, undifferentiated type, T4, and tumor marker (CEA and CA19-9) elevation were identified as independent prognostic factors for OS among patients with LRRC.
局部复发性直肠癌(LRRC)对预后和生活质量有巨大影响。由于发病率低和各种复发模式,LRRC 的治疗结果尚未完全阐明。本研究旨在评估 LRRC 患者的预后并确定预后因素。
我们在日本 24 家医院进行了一项多中心研究。招募了 1997 年至 2012 年间接受根治性切除且仅首次复发为局部复发的原发性直肠癌患者。本研究的主要结局是 LRRC 诊断后的总生存(OS)。
本研究共纳入 498 例患者。其中 213 例(42.8%)接受了手术切除;这与最佳 5 年 OS 率 52%相关,其次是碳离子/质子治疗(44%)。在 LRRC 患者中,未分化型、T4、高 CEA 水平和高 CA19-9 水平是 OS 的独立预后因素(风险比(HR)=1.83,P=0.008,HR=1.54,P=0.004,HR=1.35,P=0.03,HR=1.58,P=0.003)。
这项大规模队列研究表明,与其他 LRRC 治疗方法相比,手术切除可带来更好的预后。因此,对于 LRRC 患者,应考虑手术切除。此外,未分化型、T4 和肿瘤标志物(CEA 和 CA19-9)升高被确定为 LRRC 患者 OS 的独立预后因素。